Edwyn

Edwyn Search SEC Edgar companies...⌘K

Investing IdeasCompare Stocks

NVDA TSLA AAPL

Overview

ValuationValuation Calculator Relative Valuation Intrinsic Value (DCF)

FinancialsIncome Statement Balance Sheet Cash Flow

Explore Demo

Relative Valuation

RGNX Relative Valuation

Compare public peers against market pricing to see what the current peer set implies for fair value.

Adjust Assumptions

Peer Assumption Controls

Adjust the usable peer mix to instantly see how different valuation multiples impact the blended fair value.

Peer-Implied Fair Value

$35.70

Blended value per share

Peers imply 269.5% upside

Weighting Mixer

EV / EBITDA

N/A

Price / Sales

100%

Price / Earnings

N/A

Value Contribution Breakdown

Price / Sales

Implied peer value: $2.36B

$2.36B100% Weight

2 PeersView Full Peer Table

Equal-Weight Baseline

Discount 0.0% vs Base

$2.36B

This represents the simple average of all usable peer methods before your custom weighting adjustments are applied.

Base fair value / share:$35.70

Intrinsic Cross-Check

Underwrite Your Own Assumptions

Move beyond relative peer pricing. Use intrinsic valuation when you want to underwrite precise cash-flow forecasts, discount rates, and complex scenario ranges.

Open Intrinsic Model

Spreadsheet Data

Underlying Peer Data

Audit the saved peer set and the method inputs behind the blended fair value.

Peer data table

Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.

Peer	Price	Market Cap	Enterprise Value	Revenue	EBITDA	Net Income	P/E	P/S

Weighted Averages

See which peer averages feed the weighted fair value and which methods are excluded.

Method	Type	Avg. Multiple	Coverage	Implied Equity Value	Fair Value / Share	Status

Peer data table

Open the saved peer table used to audit the fair value view.

Peer	Price	Market Cap	Enterprise Value	Revenue	EBITDA	Net Income	P/E	P/S

Weighted Averages

Open the peer-average inputs behind the weighted result.

Method	Type	Avg. Multiple	Coverage	Implied Equity Value	Fair Value / Share	Status

Adjust Assumptions

Peer Assumption Controls

Adjust the usable peer mix to instantly see how different valuation multiples impact the blended fair value.

Peer-Implied Fair Value

$35.70

Blended value per share

Peers imply 269.5% upside

Weighting Mixer

EV / EBITDA

N/A

Price / Sales

100%

Price / Earnings

N/A

Value Contribution Breakdown

Price / Sales

Implied peer value: $2.36B

$2.36B100% Weight

2 PeersView Full Peer Table

Equal-Weight Baseline

Discount 0.0% vs Base

$2.36B

This represents the simple average of all usable peer methods before your custom weighting adjustments are applied.

Base fair value / share:$35.70

Intrinsic Cross-Check

Underwrite Your Own Assumptions

Move beyond relative peer pricing. Use intrinsic valuation when you want to underwrite precise cash-flow forecasts, discount rates, and complex scenario ranges.

Open Intrinsic Model

Spreadsheet Data

Underlying Peer Data

Audit the saved peer set and the method inputs behind the blended fair value.

Peer data table

Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.

Peer	Price	Market Cap	Enterprise Value	Revenue	EBITDA	Net Income	P/E	P/S

Weighted Averages

See which peer averages feed the weighted fair value and which methods are excluded.

Method	Type	Avg. Multiple	Coverage	Implied Equity Value	Fair Value / Share	Status

Peer data table

Open the saved peer table used to audit the fair value view.

Peer	Price	Market Cap	Enterprise Value	Revenue	EBITDA	Net Income	P/E	P/S

Weighted Averages

Open the peer-average inputs behind the weighted result.

Method	Type	Avg. Multiple	Coverage	Implied Equity Value	Fair Value / Share	Status

SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026	$20.86	$2.20B	$2.78B	$2.20B	-$686.34M	-$713.41M	-2.93x	1.00x	—
NT NTLA Intellia Therapeutics, Inc. FY ended Feb 13, 2026	$12.87	$1.80B	$1.46B	$67.67M	-$410.71M	-$412.69M	-3.38x	26.65x	—

SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026	$20.86	$2.20B	$2.78B	$2.20B	-$686.34M	-$713.41M	-2.93x	1.00x	—
NT NTLA Intellia Therapeutics, Inc. FY ended Feb 13, 2026	$12.87	$1.80B	$1.46B	$67.67M	-$410.71M	-$412.69M	-3.38x	26.65x	—